Cloud-Clone launches 13-plex bone metabolism assay

Cloud-Clone says its new 13-plex bone metabolism assay can measure 13 biomarkers in one run with 25 μL of sample, aiming to give researchers a fuller view of bone remodelling. The panel is positioned for osteoporosis, fracture repair and other metabolic bone disease studies, where single-marker testing can miss key signals.

Why it matters: - Bone metabolism is driven by a network of formation, resorption, signalling, inflammation and energy pathways, so single-marker tests can miss important biology. - Cloud-Clone is targeting a research gap in bone disease profiling, where better biomarker coverage could improve subtype analysis, drug-response tracking and fracture-risk research. - The panel is aimed at basic research and translational medicine, where precious samples and limited readouts are common constraints.

What happened: - Cloud-Clone introduced a 13-plex bone metabolism assay for simultaneous quantification of 13 biomarkers. - The company says the panel covers six research dimensions in one workflow. - The assay is designed for use in studies of osteoporosis, osteomalacia, bone erosion, diabetic osteopathy, renal osteopathy, rheumatoid-arthritis-related bone damage, hypophosphataemic bone disease and fracture repair.

The details: - The assay measures ACP5, ALPL, CTXI, DKK1, IL6, LEP, OC, OPG, OPN, PDGF BB, PINP, RANKL and SOST. - Bone-formation markers in the panel include ALPL, PINP and OC. - Bone-resorption markers include ACP5 and CTX-I. - The signaling-related markers include RANKL, OPG, SOST and DKK1. - The inflammation-related marker is IL6. - LEP is included for fat-bone crosstalk studies. - OPN and PDGF BB are included for bone-repair and fracture-healing research. - The assay uses 25 μL of sample for simultaneous detection of 13 analytes. - Cloud-Clone says the panel offers a 1000-10000-fold wider dynamic range and 10-100-fold higher sensitivity than conventional ELISA. - The company says cross-interference is minimized and results are highly reproducible. - The assay is compatible with bead-based multiplex platforms and flow cytometers. - Cloud-Clone says no additional large-scale capital equipment investment is required.

Between the lines: - The launch reflects a broader shift in bone research from static bone mineral density testing toward multiplex molecular profiling. - Cloud-Clone is positioning bead-based multiplex assays as a way to connect bone remodeling with immune, fat and glucose-lipid interactions. - The company is also using the launch to signal broader capabilities, citing nearly two decades of multiplex-assay development, a library of more than 7,000 assay targets and more than 350 validated pre-configured multiplex panels.

What's next: - Cloud-Clone says the panel is intended to support early-disease-risk prediction, clinical molecular subtyping, dynamic drug-response monitoring and novel-drug target discovery. - The company says it will continue developing multiplex assays and technical services for bone-metabolism research. - More information is available in the company's announcement.